ASSOCIATION BETWEEN ANTIHYPERTENSIVE AND LIPID-LOWERING THERAPY, BONE MASS, AND OSTEOPOROSIS RISK FACTORS
Aim. To evaluate the association between β-adrenoblocker (β-AB), angiotensin-converting enzyme inhibitor (ACEI), and statin therapy, bone mineral density (BMD), and osteoporosis risk factors (RFs).Material and methods. This retrospective study (n=1163) included 42 men and 1121 women aged >40...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2013-10-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/235 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839578043331379200 |
|---|---|
| author | K. E. Sobchenko I. A. Skripnikova V. E. Novikov T. V. Popkova I. S. Dydykina A. V. Smirnov V. A. Vygodin E. L. Nasonov S. A. Boytsov |
| author_facet | K. E. Sobchenko I. A. Skripnikova V. E. Novikov T. V. Popkova I. S. Dydykina A. V. Smirnov V. A. Vygodin E. L. Nasonov S. A. Boytsov |
| author_sort | K. E. Sobchenko |
| collection | DOAJ |
| description | Aim. To evaluate the association between β-adrenoblocker (β-AB), angiotensin-converting enzyme inhibitor (ACEI), and statin therapy, bone mineral density (BMD), and osteoporosis risk factors (RFs).Material and methods. This retrospective study (n=1163) included 42 men and 1121 women aged >40 years, who underwent densitometry before the start of the osteoporosis therapy. The main group (MG) included 418 people receiving β-AB, ACEI, statins, or their combination for at least 6 months before densitometry. The control group (CG) included 745 untreated patients. The data on RFs and pharmacological therapy came from ambulatory case histories and telephone surveys. BMD was measured by X-ray densitometry of lumbar spine and femur.Results. In patients who received antihypertensive (AHT) and lipid-lowering therapy (LLT), the risk of bone mass (BM) reduction was lower than that in CG (odds ratio (OR) 1,6; 95% confidence interval 1,25–2,022; p<0,001); the osteoporosis incidence was 1,3 times lower; and all BMD measurements were significantly higher than in untreated patients. The highest BMD was observed in patients on combined therapy which included statins. The odds of BM reduction by such factors as age, postmenopause duration, early and surgical menopause, low body mass, low physical activity (LPA), previous fractures, fractures in relatives, rheumatoid arthritis, glucocorticoid therapy, and alcohol abuse, were similar in MG and CG. In logistic regression analyses, these factors were not associated with the protective effects of the medications on BMD. The number of peripheral fractures was higher in MG than in CG (36% vs. 26%). This was due to the fact that in the MG, patients were older (mean age 62,5±8,52 years, vs. 57,8±8,2 years in CG), more likely to report LPA (>50%), and potentially, more prone to adverse effects of AHT which could result in more frequent falls.Conclusion. Treatment with β-AB, ACEI, and statins is associated with higher BMD of both lumbar spine and proximal femur. With the exception of age and postmenopause duration, osteoporosis RFs did not influence the effects of cardiovascular treatment. |
| format | Article |
| id | doaj-art-fd1ad1e346c543f2997d8d6af30412dd |
| institution | Matheson Library |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2013-10-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-fd1ad1e346c543f2997d8d6af30412dd2025-08-04T12:50:19Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252013-10-01125495510.15829/1728-8800-2013-5-49-55234ASSOCIATION BETWEEN ANTIHYPERTENSIVE AND LIPID-LOWERING THERAPY, BONE MASS, AND OSTEOPOROSIS RISK FACTORSK. E. Sobchenko0I. A. Skripnikova1V. E. Novikov2T. V. Popkova3I. S. Dydykina4A. V. Smirnov5V. A. Vygodin6E. L. Nasonov7S. A. Boytsov8State Research Centre for Preventive MedicineState Research Centre for Preventive MedicineState Research Centre for Preventive MedicineV.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, MoscowV.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, MoscowV.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, MoscowState Research Centre for Preventive MedicineV.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, MoscowState Research Centre for Preventive MedicineAim. To evaluate the association between β-adrenoblocker (β-AB), angiotensin-converting enzyme inhibitor (ACEI), and statin therapy, bone mineral density (BMD), and osteoporosis risk factors (RFs).Material and methods. This retrospective study (n=1163) included 42 men and 1121 women aged >40 years, who underwent densitometry before the start of the osteoporosis therapy. The main group (MG) included 418 people receiving β-AB, ACEI, statins, or their combination for at least 6 months before densitometry. The control group (CG) included 745 untreated patients. The data on RFs and pharmacological therapy came from ambulatory case histories and telephone surveys. BMD was measured by X-ray densitometry of lumbar spine and femur.Results. In patients who received antihypertensive (AHT) and lipid-lowering therapy (LLT), the risk of bone mass (BM) reduction was lower than that in CG (odds ratio (OR) 1,6; 95% confidence interval 1,25–2,022; p<0,001); the osteoporosis incidence was 1,3 times lower; and all BMD measurements were significantly higher than in untreated patients. The highest BMD was observed in patients on combined therapy which included statins. The odds of BM reduction by such factors as age, postmenopause duration, early and surgical menopause, low body mass, low physical activity (LPA), previous fractures, fractures in relatives, rheumatoid arthritis, glucocorticoid therapy, and alcohol abuse, were similar in MG and CG. In logistic regression analyses, these factors were not associated with the protective effects of the medications on BMD. The number of peripheral fractures was higher in MG than in CG (36% vs. 26%). This was due to the fact that in the MG, patients were older (mean age 62,5±8,52 years, vs. 57,8±8,2 years in CG), more likely to report LPA (>50%), and potentially, more prone to adverse effects of AHT which could result in more frequent falls.Conclusion. Treatment with β-AB, ACEI, and statins is associated with higher BMD of both lumbar spine and proximal femur. With the exception of age and postmenopause duration, osteoporosis RFs did not influence the effects of cardiovascular treatment.https://cardiovascular.elpub.ru/jour/article/view/235β-adrenoblockersangiotensin-converting enzyme inhibitorsstatinsbone mineral densityosteoporosisosteoporotic fractures |
| spellingShingle | K. E. Sobchenko I. A. Skripnikova V. E. Novikov T. V. Popkova I. S. Dydykina A. V. Smirnov V. A. Vygodin E. L. Nasonov S. A. Boytsov ASSOCIATION BETWEEN ANTIHYPERTENSIVE AND LIPID-LOWERING THERAPY, BONE MASS, AND OSTEOPOROSIS RISK FACTORS Кардиоваскулярная терапия и профилактика β-adrenoblockers angiotensin-converting enzyme inhibitors statins bone mineral density osteoporosis osteoporotic fractures |
| title | ASSOCIATION BETWEEN ANTIHYPERTENSIVE AND LIPID-LOWERING THERAPY, BONE MASS, AND OSTEOPOROSIS RISK FACTORS |
| title_full | ASSOCIATION BETWEEN ANTIHYPERTENSIVE AND LIPID-LOWERING THERAPY, BONE MASS, AND OSTEOPOROSIS RISK FACTORS |
| title_fullStr | ASSOCIATION BETWEEN ANTIHYPERTENSIVE AND LIPID-LOWERING THERAPY, BONE MASS, AND OSTEOPOROSIS RISK FACTORS |
| title_full_unstemmed | ASSOCIATION BETWEEN ANTIHYPERTENSIVE AND LIPID-LOWERING THERAPY, BONE MASS, AND OSTEOPOROSIS RISK FACTORS |
| title_short | ASSOCIATION BETWEEN ANTIHYPERTENSIVE AND LIPID-LOWERING THERAPY, BONE MASS, AND OSTEOPOROSIS RISK FACTORS |
| title_sort | association between antihypertensive and lipid lowering therapy bone mass and osteoporosis risk factors |
| topic | β-adrenoblockers angiotensin-converting enzyme inhibitors statins bone mineral density osteoporosis osteoporotic fractures |
| url | https://cardiovascular.elpub.ru/jour/article/view/235 |
| work_keys_str_mv | AT kesobchenko associationbetweenantihypertensiveandlipidloweringtherapybonemassandosteoporosisriskfactors AT iaskripnikova associationbetweenantihypertensiveandlipidloweringtherapybonemassandosteoporosisriskfactors AT venovikov associationbetweenantihypertensiveandlipidloweringtherapybonemassandosteoporosisriskfactors AT tvpopkova associationbetweenantihypertensiveandlipidloweringtherapybonemassandosteoporosisriskfactors AT isdydykina associationbetweenantihypertensiveandlipidloweringtherapybonemassandosteoporosisriskfactors AT avsmirnov associationbetweenantihypertensiveandlipidloweringtherapybonemassandosteoporosisriskfactors AT vavygodin associationbetweenantihypertensiveandlipidloweringtherapybonemassandosteoporosisriskfactors AT elnasonov associationbetweenantihypertensiveandlipidloweringtherapybonemassandosteoporosisriskfactors AT saboytsov associationbetweenantihypertensiveandlipidloweringtherapybonemassandosteoporosisriskfactors |